Medication info

Romitel Tablets 80/20 mg (Telmisartan, Rosuvastatin Calcium)

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Kolon Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 202005524 · Approved 2020.07.29

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular disease risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular disease morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular disease risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Kolon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • stroke
  • myocardial infarction
View approved original text

This medication is used for patients who require simultaneous treatment with Telmisartan and Rosuvastatin. Telmisartan is primarily used for the treatment of essential hypertension and helps reduce the risk of myocardial infarction, stroke, and mortality due to cardiovascular diseases in high-risk patients. Rosuvastatin is used as an adjunct to dietary therapy for hypercholesterolemia, particularly in familial hypercholesterolemia and mixed dyslipidemia, lowering LDL cholesterol and total cholesterol levels to delay the progression of atherosclerosis. Additionally, it contributes to reducing the risks of stroke, myocardial infarction, and peripheral vascular revascularization in middle-aged patients with elevated high-sensitivity C-reactive protein levels at high risk of cardiovascular disease. Thus, this medication effectively improves cardiovascular health through blood pressure and lipid management.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular disease risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular disease morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular disease risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to fetuses and newborns if given to pregnant women, so it should be discontinued immediately upon confirmation of pregnancy. Women with allergies to any components of this medication, those who are pregnant or nursing, or women of childbearing potential not using adequate contraception should not take this medication. Patients with severe liver impairment, bile obstruction, muscle diseases, severe renal impairment, or those taking certain concomitant medications should not use this medication. Elderly patients, those with high potassium levels, and patients with mild liver dysfunction should use this medication with caution and undergo regular liver function tests and muscle-related tests. This medication may cause symptoms such as myalgia, muscle weakness, or muscle cramps, so if such symptoms occur, consult a doctor immediately. During the use of this medication, liver function and muscle condition should be regularly monitored for abnormalities, and especially if muscle enzyme levels significantly increase above normal, medication should be discontinued. Interactions may occur when taken with other antihypertensives or lipid-lowering medications, so it is vital to inform your doctor about any other medications being taken. This medication can lower blood pressure, which may result in symptoms of hypotension, particularly in patients who are dehydrated or have low blood volume. It is recommended not to take this medication within 24 hours prior to surgery; patients at risk of acute renal deterioration should use this medication with caution. Women who may become pregnant should use adequate contraception while taking this medication and discontinue it immediately upon confirmation of pregnancy. This medication is not recommended for children as its safety and efficacy have not been established. In case of overdose, symptoms such as hypotension, dizziness, and arrhythmias may occur, and immediate medical attention is necessary. During the use of this medication, caution is advised in driving or operating machinery due to possible dizziness or drowsiness.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, increased ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorder, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver dysfunction, increased sweating, itching, rash, erythema, angioedema, drug eruption, toxic skin eruption, eczema, urticaria, myalgia, lumbar pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, insufficient effect, headache, dizziness, cough, dyspepsia, palpitations, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is essential to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.